Regulation
TrumpRx drug prices beat other wealthy nations on fewer than half of listed drugs, KFF finds
By Insurance Wire Staff, . Insurance Wire.
The TrumpRx website, promoted by the Trump administration as a route to the world's lowest prescription drug prices through voluntary "Most Favored Nation" pricing agreements with manufacturers, does not consistently deliver cheaper prices than those available in other wealthy nations, according to a new analysis published by KFF.
KFF compared prices for 32 brand-name drugs listed on TrumpRx as of August 25, 2026, selecting only those without a generic or biosimilar available in the United States and with publicly listed prices in at least one of eleven comparator countries: Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. The result, KFF found, is that consumers buying through TrumpRx are about as likely to pay more as to pay less relative to those international benchmarks.
For many of the drugs on the site, TrumpRx directs consumers to manufacturer discount coupons redeemable at a pharmacy without using insurance, rather than to a negotiated government price. KFF notes an important methodological caveat: the international prices used in the comparison are often the rates paid by a national health system or equivalent body, not necessarily what an individual consumer in that country pays out of pocket under their own coverage.
The analysis does not compare TrumpRx prices to what U.S. consumers may have paid before the site launched, so it does not speak to whether the program has reduced domestic prices from a prior baseline.
For carriers and pharmacy benefit managers, the practical implication is that TrumpRx functions more as a supplemental coupon channel than as a structural repricing mechanism. Drugs routed through manufacturer coupons sit outside standard formulary and rebate arrangements, which means plan sponsors and their advisors cannot assume TrumpRx participation translates into lower net costs at the plan level. The harder question the analysis leaves open is whether the voluntary pricing agreements underpinning the site will expand, tighten, or stall, and whether future iterations will move toward the statutory price-setting models that produce the lower international benchmarks KFF used for comparison.
No official data yet establishes how many consumers have used TrumpRx, what share of participating manufacturers have extended their agreements beyond the initial launch drugs, or how the coupon prices on the site compare to what those same consumers would have paid through their existing coverage.
The full analysis is available through the Peterson-KFF Health System Tracker.
Insurance Wire provides news and information, not insurance, legal, or financial advice. Consult a qualified professional about your specific needs.